Hematologic Malignancy
Follicular Helper T-Cell Lymphoma
CI-CAN-00007714Explore in graph →
Hematologic17 active trials
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00007714Explore in graph →
Rankings
9 current ranking rows (latest year per scope). Each row lists the scope, the formula version, the value and the exact inputs that produced it.
| Metric | Scope | Rank / eligible | Δ | Value | Percentile | Confidence | Formula | Generated | Inputs |
|---|---|---|---|---|---|---|---|---|---|
| Publications, last 12 months | World · both sexes · all ages · latest · all malignant entities | #915 / 2,294 | = | 12 count | 60.1 | Medium confidence | ci-pubs-12m-v1 | Sep 30, 2026 | showformula: literature_counts.count WHERE window_key = 12m
inputs hash b1963bee32e72b8b6e51efec Trace lineage (admin) |
| Publications, last 5 years | World · both sexes · all ages · latest · all malignant entities | #928 / 2,873 | = | 59 count | 67.7 | Medium confidence | ci-pubs-5y-v1 | Sep 30, 2026 | showformula: literature_counts.count WHERE window_key = 5y (query stored per row)
inputs hash 7b01855837dd178dff17a0c3 Trace lineage (admin) |
| Publication growth | World · both sexes · all ages · latest · all malignant entities | #124 / 286 | = | 1.18 ratio | 56.8 | Medium confidence | ci-pub-growth-v1 | Sep 30, 2026 | showformula: publications_12m / (publications_5y_prior / 5)
inputs hash f24de54682c3ca3c4a7306df Trace lineage (admin) |
| Active clinical trials | World · both sexes · all ages · latest · all malignant entities | #469 / 1,654 | = | 17 count | 71.7 | Medium confidence | ci-active-trials-v1 | Sep 30, 2026 | showformula: COUNT(DISTINCT trial) FROM trial_conditions JOIN clinical_trials WHERE cancer_id IN descendants(cancer) AND study_type = INTERVENTIONAL AND overall_status IN (RECRUITING, NOT_YET_RECRUITING, ENROLLING_BY_INVITATION, ACTIVE_NOT_RECRUITING)
inputs hash d8f333d5bfdbadb41c05f9e2 Trace lineage (admin) |
| Active Phase III trials | World · both sexes · all ages · latest · all malignant entities | #403 / 810 | = | 2 count | 50.3 | Medium confidence | ci-phase3-trials-v1 | Sep 30, 2026 | showformula: COUNT(DISTINCT trial) … active statuses AND PHASE3 = ANY(phases)
inputs hash 55bad1a93f2cbb5682249863 Trace lineage (admin) |
| Recruiting clinical trials | World · both sexes · all ages · latest · all malignant entities | #444 / 1,284 | = | 10 count | 65.5 | Medium confidence | ci-recruiting-trials-v1 | Sep 30, 2026 | showformula: COUNT(DISTINCT trial) … overall_status = RECRUITING AND study_type = INTERVENTIONAL
inputs hash 00002505dcded3e0217a182d Trace lineage (admin) |
| Recruiting Phase III trials | World · both sexes · all ages · latest · all malignant entities | #281 / 585 | = | 2 count | 52.1 | High confidence | ci-phase3-recruiting-v1 | Sep 30, 2026 | showformula: COUNT(DISTINCT trial) … overall_status = RECRUITING AND PHASE3 = ANY(phases) AND study_type = INTERVENTIONAL
inputs hash 3f7191c10405ddd12eec0cad Trace lineage (admin) |
| Sponsor concentration (HHI) | World · both sexes · all ages · latest · all malignant entities | #106 / 614 | = | 0.142 index (0–1) | 82.9 | Medium confidence | ci-sponsor-hhi-v1 | Sep 30, 2026 | showformula: Σ (active_trials_by_lead_sponsor / active_trials)² over the cancer and its descendants
|
| Trial termination share | World · both sexes · all ages · latest · all malignant entities | #384 / 454 | = | 0.28 ratio | 15.5 | Medium confidence | ci-trial-termination-v1 | Sep 30, 2026 | showformula: (terminated + withdrawn) / (completed + terminated + withdrawn) WHERE first_posted_date ≥ 2010-01-01 AND study_type = INTERVENTIONAL
|
Computed Ranks are competition ranks (ties share a rank). Percentile = share of eligible entities ranked at or below this one in the ranking direction.
"Deadliest" is ambiguous: annual deaths, age-standardized mortality rate, mortality-to-incidence ratio and 5-year survival rank cancers differently. CancerIndex publishes each as a separate metric.
inputs hash 909c6c96975dbbd1461c83c4
inputs hash aebac3d92951539ea771c6d9
Unmet need · computed
No research-gap components for this entity